As Pharmacosmos Therapeutics looks to enter the oncology market, the company has entered into a definitive merger agreement with G1 Therapeutics, with the former’s US subsidiary acquiring all outstanding shares of G1 for approximately $405m.
Pharmacosmos is expected to pay $7.15 per share of G1’s common stock, a 68% premium to G1’s closing share price of $4.25 on 6 August. The deal is expected to close in Q3 this year and will be an all-cash transaction funded through Pharmacosmos’s existing cash reserves along with its existing corporate credit facilities.
The deal is centred around G1’s lead cyclin-dependent kinase 4/6 (CDK4/6) inhibitor Cosela (trilaciclib). The US Food and Drug Administration (FDA) approved Cosela to decrease the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC), in 2021.
Cosela raked in $46.3m in sales last year, as per G1’s financials. GlobalData expects the therapy sales to increase exponentially, with Cosela expected to pull in over $471m by 2030.
GlobalData is the parent company of Pharmaceutical Technology.
Following the deal close, Cosela will be the second FDA-approved product and the first oncology therapy, in Pharmacosmos’s pipeline. The only other FDA-approved therapy in the company’s portfolio is Monoferric (ferric derisomaltose) indicated to treat iron deficiency anaemia.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Recently, G1 suffered a major setback in Cosela development when the therapy failed to show efficacy in patients with metastatic triple-negative breast cancer (TNBC). In June, the Phase III Preserve-2 trial (NCT04799249) failed to meet the primary endpoint of overall survival (OS), with a median OS of 17.4 months in the Cosela arm compared with 17.8 months in the control arm.
Another therapy in Pharmacosmos’s pipeline is transfusion-dependent β-thalassemia therapy, SP-420. The company gained the therapy as part of the acquisition of AbFero Pharmaceuticals, in 2021. SP-420’s ability to remove iron from organs in subjects with transfusion-dependent β-thalassemia is being evaluated in a Phase II trial (NCT05693909).
